Aelis Farma is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain and peripheral disorders by targeting the CB1 receptor. Their proprietary platform generates Signaling Specific inhibitors of the CB1 receptor (CB1-SSi), which mimic a natural brain defense mechanism to treat various neurological conditions without disrupting normal behavior. The company's lead candidates, AEF0117 and AEF0217, are in advanced clinical trials for cannabis use disorders and cognitive deficits, respectively.